Silverback Therapeutics, Inc. announced Thilo Schroeder, Ph.D. will not stand for re-election as a member of the company's board of directors when his term as a class II director expires at the company's 2022 annual meeting of stockholders and on March 14, 2022, Dr. Schroeder resigned as a member of the audit committee of the board of directors of the company to focus on other endeavors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.98 USD | 0.00% | +1.70% | +63.87% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+63.87% | 870M | |
+54.05% | 63.85B | |
-2.02% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.42% | 26.52B | |
-21.60% | 18.69B | |
+2.89% | 12.73B | |
+22.40% | 12.11B | |
+27.49% | 12.07B |
- Stock Market
- Equities
- SPRY Stock
- News ARS Pharmaceuticals, Inc.
- Silverback Therapeutics, Inc. Announces Thilo Schroeder Will Not Stand for Re-Election as Member of the Company Board of Directors